Tidal Investments LLC Lowers Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Tidal Investments LLC decreased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 46.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,334 shares of the biotechnology company’s stock after selling 33,710 shares during the quarter. Tidal Investments LLC’s holdings in ADMA Biologics were worth $766,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of ADMA Biologics in the second quarter valued at about $29,000. Hollencrest Capital Management purchased a new stake in ADMA Biologics during the 3rd quarter valued at approximately $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth approximately $31,000. National Bank of Canada FI purchased a new position in shares of ADMA Biologics in the 3rd quarter valued at approximately $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the third quarter valued at approximately $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

ADMA has been the subject of several recent research reports. Raymond James increased their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Trading Down 2.8 %

Shares of ADMA stock opened at $17.40 on Friday. The business’s fifty day moving average price is $18.92 and its 200 day moving average price is $16.30. The firm has a market capitalization of $4.11 billion, a PE ratio of 62.14 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1-year low of $4.07 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the prior year, the company posted $0.01 EPS. As a group, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.